Investors & Media

Corporate Profile
Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440... More >>
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$18.34
Change (%) Stock is Up 0.17 (0.94%)
Volume37,802
Data as of 08/30/16 10:38 a.m. ET
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation (August 2016)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
08/10/16Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today reported business progress and financial results for the second quarter ended June 30, 2016. “We made important progress across our GBT440 development programs and strengthened our balance sheet with the completion of our financing in ... 
Printer Friendly Version
08/09/16Global Blood Therapeutics to Present at the Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that its president and chief executive officer, Ted W. Love, M.D. will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 16 at 1:20 p.m. Eastern Time.  The presentation will be webcast live and available... 
Printer Friendly Version
07/08/16Global Blood Therapeutics Announces Publication of Preclinical GBT440 Results in British Journal of Haematology that Support Sickle Cell Disease (SCD) Program
Data Suggest the Potential of GBT440 to Reduce Sickling, Extend the Circulating Half-Life of Red Blood Cells and Decrease Excessive Erythropoiesis in SCD SOUTH SAN FRANCISCO, Calif., July 8, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced publication of preclinical GBT440 results in sickle cell disease (SCD) in th... 
Printer Friendly Version
06/29/16Global Blood Therapeutics Announces Initiation of Phase 2a Study of GBT440 in Adolescents with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2016 /PRNewswire/ -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced it has initiated a Phase 2a study of GBT440 in adolescents with sickle cell disease (SCD). GBT is developing GBT440 as a potential disease-modifying therapy for SCD. "We are pleased to initiate our Phase 2a study of GBT440 in ado... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.